三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
国内真实世界一线和二线治疗EGFRex20ins患者的PFS
国内真实世界一线和二线治疗EGFRex20ins患者的PFS
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:468KB
图片尺寸:2268*871
同报告图片
/
4
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
所属报告:
医药行业创新药前沿专题:从难治到突破EGFR 20外显子插入突变正被攻克-221227(29页).pdf
打包全文图表
相关数据
依沃西为全球首个在三期临床中头对头击败K药的新药,PFS强阳性(HR=0.51)
收藏
行业数据
2026-03-31
原图定位
查看详情
HARMONi-6试验主要终点:依沃西+化疗较对照臂PFS提升4.2个月(HR=0.60)
收藏
行业数据
2026-03-31
原图定位
查看详情
CARTITUDE-4 TME: Patients With Shorter PFS (≤18M) and Patients With More pLOT had a More Suppressive TME
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
收藏
行业数据
2026-03-11
原图定位
查看详情
CARTITUDE-4: PFS and OS in Patients With Standard-Risk Cytogenetics (As-Treated)
fCDnu4TliKsgfCAzMOS4quaciOaXoOi/m+WxleeUn+WtmOeOh++8iFBGUywgJe+8iSB8IDMw5Liq5pyI5oC755Sf5a2Y546H77yIT1MsICXvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSB8IDgwLjUgfCA4Ny4zIHwKfCBDQVJUSVRVREUgLSA0IOagh+WHhumjjumZqSArIGdhaW4vYW1wKDFxKSB8IDcxLjcgfCA4Ni4xIHwKCui1hOaWmeadpea6kO+8mlBBUlRJVFVERSAtIDQg56CU56m277yI5qCH5YeG6aOO6Zmp57uG6IOe6YGX5Lyg5a2m5oKj6ICFIEFzIC0gVHJlYXRlZCDliIbmnpDvvInmlbDmja4=
收藏
行业数据
2026-03-11
原图定位
查看详情
Figure 3: PFS (A) and OS (B)
fCDmjIfmoIcgICAgICAgfCAzNuS4quaciOeOhyB8IDk1JSDnva7kv6HljLrpl7QgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18CnwgUEZTICAgICAgICB8IDkzLjglICAgIHwgNjMuMuKAkzk5LjEgICAgfAp8IE9TICAgICAgICAgfCA5My44JSAgICB8IDYzLjLigJM5OS4xICAgIHwKCui1hOaWmeadpea6kO+8muWbvueJh+S4reKAnFJlc3VsdHPigJ3mnb/lnZflj4pGaWd1cmUgM++8iFBGUyAoQSkg5ZKMIE9TIChCKe+8ieWGheWuueOAgg==
收藏
行业数据
2026-03-11
原图定位
查看详情
T-DXd对HER2-lowBC的全人群PFS
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
收藏
行业数据
2025-11-24
原图定位
查看详情
Ivonescimab国内临床,PFS显著优于K药
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
收藏
行业数据
2025-10-24
原图定位
查看详情
izabren展现EGFRmNSCLC二线治疗历史最长PFS(单位:月)
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
收藏
行业数据
2025-09-16
原图定位
查看详情
Vepdegestrantvs氟维司群在HR+/HER2-BC(全人群)的PFS数据
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
收藏
行业数据
2025-08-08
原图定位
查看详情
R/RCLL最新PFS数据支持BGB-16673开展与匹妥布替尼的头对头试验
fCDpobnnm64gfCBCR0ItMTY2NzMgfCDljLnlronluIPmm7/lsLwgfAp8LS0tLS0tfC0tLS0tLS0tLS18LS0tLS0tLS0tLXwKfCBuICAgIHwgNjYgICAgICAgfCAxMTkgICAgICB8Cnwg5Lit5L2NUEZTLCDmnIggKDk1JSBDSSkgfCAyMi44ICgxNS42KSB8IDE0LjAgKDExLjItMTYuNikgfAp8IOS4reS9jemaj+iuv+aXtumXtCwg5pyIIHwgMTUuNiAgICAgIHwgMTkuNCAgICAgIHw=
收藏
行业数据
2025-08-07
原图定位
查看详情
CELESTIAL-301临床:全球唯一旨在证明相比目前固定疗程标准疗法具有PFS
fCDliIblsYLlm6DntKAgfCBB57uEIHwgQue7hCB8CnwtLS0tLS0tLS0tLXwtLS0tLXwtLS0tLXwKfCDlubTpvoQoPDY15bKB5a+55q+U4omlNjXlsoEpIHwgICAgIHwgICAgIHwKfCBJR0hWKOeqgeWPmOWvueavlOacqueqgeWPmCkgfCAgICAgfCAgICAgfAp8IOaYr+WQpuS8tOaciTE3cOe8uuWksS9UUDUz56qB5Y+YIHwgICAgIHwgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOa8lOekuuadkOaWme+8jOWbvemHkeivgeWIuOeglOeptuaJgA==
收藏
行业数据
2025-08-07
原图定位
查看详情
无明确驱动基因NSCLC(无论PD-L1表达状态),依沃西PFS数据佳,SSGJ-707的ORR及安全性佳
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
收藏
行业数据
2025-07-17
原图定位
查看详情
Tarlatamab在PFS及癌症相关呼吸/咳嗽获益
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
收藏
行业数据
2025-07-15
原图定位
查看详情
戈利昔替尼与西达本胺的PFS曲线对比
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
收藏
行业数据
2025-06-23
原图定位
查看详情
外显子21(L858R)和外显子19缺失亚组PFS率对比
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
收藏
行业数据
2025-06-09
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
国内真实世界研究中,ex20ins 突变患者的获益同样较低,EGFR-TKI 预后甚至差于化疗。中国医学科学院的专家团队在 Lung Cancer 杂志发布了一项我国 EGFR ex20ins 突变最大的真实世界研究数据(图 4)。在我国 26 个地区 99 家医院共计 165 例晚期或转移性 EGFR 20 插入突变的 NSCLC 患者中,纳入研究的患者接受过化疗、靶向治疗或免疫检查点抑制剂治疗,其中化疗方案主要包含了培美曲塞、紫杉醇、多西他赛、白蛋白紫杉醇与吉西他滨,铂类和贝伐珠单抗;靶向治疗方案包括了吉非替尼、厄洛替尼、埃克替尼、阿法替尼和奥希替尼在内的EGFR-TKI,也有部分患者接受了O药和K药在内的免疫治疗。研究发现,一线化疗 mPFS 为 6.4 个月、ORR 为 19.2%,一线 EGFR-TKI 治疗 mPFS 为2.9 个月、ORR 为 8.7%;二线化疗 mPFS 为 4.0 个月、ORR 为 17.6%,二线 EGFR-TKI治疗 mPFS 为 2.0 个月、ORR 为 5.9%。无论是一线还是二线治疗接受 EGFR 抑制剂患者的预后甚至比化疗更差。
行业数据
原图定位
当前图表所属:
医药行业创新药前沿专题:从难治到突破EGFR 20外显子插入突变正被攻克-221227(29页).pdf
国内正在进行的ex20ins适应症临床试验
真实世界研究中不同EGFR亚型患者的临床获益
已上市EGFR抑制剂治疗ex20ins突变NSCLC患者疗效
现有三代EGFR抑制剂的获批适应症
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》